Chardan Capital Has Negative Outlook of ALUR FY2025 Earnings

Allurion Technologies, Inc. (NYSE:ALUR) – Equities research analysts at Chardan Capital decreased their FY2025 earnings estimates for shares of Allurion Technologies in a research note issued on Monday, August 11th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($2.08) per share for the year, down from their previous estimate of ($0.75). The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share. Chardan Capital also issued estimates for Allurion Technologies’ FY2026 earnings at ($3.37) EPS.

Separately, Wall Street Zen raised shares of Allurion Technologies from a “strong sell” rating to a “hold” rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.83.

Allurion Technologies Price Performance

ALUR opened at $2.48 on Thursday. The firm has a fifty day moving average price of $2.71 and a 200 day moving average price of $3.05. Allurion Technologies has a 1 year low of $2.15 and a 1 year high of $22.25. The stock has a market cap of $18.50 million, a P/E ratio of -0.20 and a beta of -0.45.

Allurion Technologies (NYSE:ALUR) last posted its earnings results on Wednesday, May 14th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.53) by $1.96. The firm had revenue of $5.58 million during the quarter, compared to analyst estimates of $5.50 million.

Hedge Funds Weigh In On Allurion Technologies

A hedge fund recently raised its stake in Allurion Technologies stock. XTX Topco Ltd lifted its holdings in shares of Allurion Technologies, Inc. (NYSE:ALUR) by 43.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,670 shares of the company’s stock after acquiring an additional 5,633 shares during the period. XTX Topco Ltd owned 0.25% of Allurion Technologies worth $45,000 at the end of the most recent reporting period. Institutional investors own 21.39% of the company’s stock.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.